Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS)
are increasingly utilized in the field of gastroenterology to diagnose and treat various
upper gastrointestinal diseases. More than 500,000 ERCPs are performed annually in
the United States for pancreaticobiliary disorders and the role of EUS has continued
to expand over the past three decades to include a wide range of diagnostic and therapeutic
interventions [1]
[2].
Non-forward-viewing ERCP duodenoscopes and EUS linear echoendoscopes are utilized
in the upper gastrointestinal tract to perform various diagnostic and therapeutic
maneuvers. Their endoscopic fields of view limit visualization of the lumen compared
to the standard upper endoscope because these endoscopes are not designed to diagnose
upper gastrointestinal tract lesions. Duodenoscopes and linear echoendoscopes are
side-viewing and oblique-viewing endoscopes, respectively, with a field of view of
100 degrees, as compared to the 140-degree field of view of the standard gastroscope
( [Table1]). In addition, these non-forward-viewing endoscopes have a larger diameter and more
rigid distal tip, limiting their maneuverability and angulation range. While these
scopes are used for specific indications, the examination of the upper gastrointestinal
tract is limited and luminal lesions may be missed. A recent study evaluating the
utility of standard upper endoscopy before EUS demonstrated that clinically meaningful
lesions were found on esophagogastroduodenoscopy (EGD) in 22 % of patients [3]. This study shows that a substantial amount of patients undergoing EUS have significant
incidental luminal lesions. However, this study did not assess whether non-forward-viewing
echoendoscopes would have missed meaningful lesions without the use of a gastroscope.
Table 1
Characteristics of the endoscopes used in the study.
|
EUS Linear Endoscope
|
ERCP duodenoscope
|
Gastroscope
|
|
Field of view
|
100°
|
100°
|
140°
|
|
Direction of view
|
forward, oblique-viewing 55°
|
backward, side-viewing 5°
|
forward-viewing
|
|
Angulation range (degree)
|
up 130°, down 90°, right 90°, left 90°
|
up 120°, down 90°, right 110°, left 90°
|
up 210°, down 90°, right 100°, left 100°
|
EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography
Although an increasing number of ERCP and EUS procedures are being performed, there
is currently no consensus on the use of a standard gastroscope in tandem with these
procedures. Thus, the prevalence of missed luminal lesions when only using a non-forward-viewing
endoscope is unclear. The purpose of the current study was to examine the prevalence
of clinically significant incidental upper gastrointestinal tract lesions that were
found using a standard forward-viewing gastroscope following an ERCP or EUS exam using
a duodenoscope or linear echoendoscope. We hypothesized prior to analyzing the data
that linear EUS and ERCP would miss significant esophageal gastrointestinal lesions
but not gastric or duodenal lesions. This was hypothesized because very little esophageal
mucosa is seen while traversing the esophagus with a linear echoendoscope or duodenoscope.
Patients and methods
This is a retrospective analysis of a single therapeutic endoscopist’s procedures
from 10/1/2013 to 6/1/2014 at a tertiary care medical center. After two missed gastric
adenocarcinomas were presented at the hospital tumor board in patients who had previously
undergone ERCPs by another gastroenterologist, the institution adopted as standard
of care routine EGD at the time of all ERCP or EUS examinations. The endoscopist chose
to perform the ERCP or EUS first before the EGD because his previous standard of care
was to perform linear EUS or ERCP without a formal EGD if the patient had no upper
gastrointestinal tract symptoms and, in the event that patient tolerability of the
procedure was not ideal and early termination of the procedure was required, the maximum
time would be allotted to the main EUS or ERCP procedure.
Patients were included in this study if they: 1) underwent ERCP and/or EUS using a
duodenoscope (TJF-Q180V, Olympus America, Center Valley, PA, USA) or a curved linear
echoendoscope (GF-UCT180, Olympus America, Center Valley, PA, USA) followed by an
EGD using a standard forward-viewing gastroscope (HQ190, Olympus America, Center Valley,
PA, USA) during a single procedure; and 2) did not have dysphagia or other upper gastrointestinal
tract symptoms. All patients were screened for dysphagia prior to undergoing the procedure.
All patients signed informed consent for ERCP and/or EUS and EGD prior to the procedure.
All patients had undergone monitored anesthesia care with propofol sedation or general
anesthesia. Patients were excluded from this analysis if: 1) they required an EGD
for diagnostic purposes; 2) they had dysphagia; 3) there was a clinical suspicion
of upper gastrointestinal tract lesions; 4) EUS was performed using a radial echoendoscope;
5) EUS exam was not a pancreaticobiliary exam; and 6) they had altered pancreaticobiliary
anatomy.
All endoscopy reports recorded endoscopic lesions detected in the upper gastrointestinal
tract. The data collected included age, gender, ethnicity, exam type, and indication
for exam. The oblique-viewing linear echoendoscope and side-viewing duodenoscope were
passed in the usual fashion for the relevant EUS and ERCP exams. Upper gastrointestinal
luminal findings visualized during passage of the scopes were recorded separately
for each procedure. Relevant histologic findings were recorded and correlated with
endoscopic findings.
The primary outcome of the study was to determine the proportion of clinically significant
missed incidental lesions when using a side- or oblique-viewing endoscope as compared
to the standard forward-viewing endoscope. Significant additional lesions found with
a forward-viewing gastroscope were defined as findings that led to a change in the
patient’s medication regimen, additional endoscopic surveillance or interventions,
or the need for other imaging studies. Gastric erythema, Helicobacter pylori-negative gastritis, hiatal hernias or other anatomic abnormalities that did not affect
management were not considered significant findings. Data analysis was performed using
SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Differences between groups were determined
by using the Student’s T test or Wilcoxon test for continuous variables and the Fisher exact test for categorical
variables. The retrospective study was approved by the Hofstra North Shore Long Island
Jewish School of Medicine institutional review board.
Results
A total of 168 patients were identified who underwent ERCP and/or EUS using a side-
or oblique-viewing endoscope followed by an EGD using a forward-viewing gastroscope
during a single procedure. The baseline patient demographics and indication for initial
procedures are included in [Table2]. Sixty-eight men (40 %) and 100 women (60 %) were identified. The median patient
age was 55 years (range: 19 – 92). The most common indications for the initial procedure
were known or suspected choledocholithiasis, pancreatic mass, chronic pancreatitis,
or evaluation of dilated pancreatic or bile ducts.
Table 2
Patient demographics and indications for each procedure.
|
Patient Demographics
|
|
|
Age (years)
|
|
|
Mean
|
57
|
|
Median
|
55
|
|
Minimum
|
19
|
|
Maximum
|
92
|
|
Gender
|
|
|
Male
|
68
|
|
Female
|
100
|
|
Race
|
|
|
Caucasian
|
53
|
|
African-American
|
50
|
|
Hispanic
|
34
|
|
Asian
|
28
|
|
Other
|
3
|
|
Indications
|
|
|
CBD stone (known/suspected)
|
54
|
|
Pancreatic mass/cyst
|
27
|
|
CBD stent/stricture/bile leak
|
20
|
|
Chronic pancreatitis
|
18
|
|
Abnormal liver enzymes/RUQ pain
|
18
|
|
Dilated PD/CBD
|
14
|
|
Cholangitis
|
8
|
|
Gallbladder mass
|
4
|
|
Other mass
|
4
|
|
Abnormal lymphadenopathy
|
3
|
|
FAP
|
1
|
|
Celiac plexus neurolysis
|
1
|
CBD, common bile duct; RUQ, right upper quadrant; PD, pancreatic duct; FAP, familial
adenomatous polyposis.
Of the 168 patients, 52 procedures were done with a duodenoscope followed by a gastroscope,
83 procedures were done with a curved linear echoendoscope followed by a gastroscope,
and 33 patients were done using both a linear echoendoscope and a duodenoscope followed
by a gastroscope. Of the latter patients, 14 (8 %) had significant incidental clinical
lesions found using a non-forward-viewing endoscope, including gastric/duodenal ulcers,
H. pylori gastritis, duodenal polyp, and an ampullary adenoma, all of which were not included
in the calculations for lesions missed by non-forward-viewing endoscopes.
Clinically significant additional lesions diagnosed with a gastroscope but missed
by a non-forward-viewing endoscope were found in 30/168 patients (18 %). [Table 3] lists the specific details. EGD with a gastroscope after a linear EUS resulted in
additional lesion findings in 17/83 patients (20.5 %, χ2 = 13.385, P = 0.00025). EGD with a gastroscope after an ERCP with a duodenoscope resulted in
additional lesions findings in 10 /52 patients (19.2 %, χ2 = 9.987, P = 0.00157). EGD with a gastroscope after the use of both a linear echoendoscope and
a duodenoscope resulted in additional lesions findings in 3/33 patients (9 %, χ2 = 3.219, P = 0.07).
Table 3
Characteristics of the pathology found organized by type of management change and
endoscope that diagnosed the lesion.
|
ERCP (n = 52)
|
Linear EUS (n = 83)
|
ERCP & EUS (n = 33)
|
Total (n = 168)
|
|
Additional Findings on EGD Prompting Change in Management
|
10 (P = 0.00157)
|
17 (P = 0.00025)
|
3 (P = 0.07)
|
30
|
|
Medication changes
|
9
|
11
|
2
|
22
|
|
Esophageal
|
4
|
5
|
2
|
11
|
|
Barrett's (2)[1]
Candida esophagitis (1) Reflux esophagitis (1)
|
Barrett's (2)[1]
Candida esophagitis (1) Reflux esophagitis (1) Ulcer (1)
|
Barrett's (2)[1]
|
|
|
Gastric
|
5
|
6
|
0
|
11
|
|
Antral gastric ulcer (2)
Fundic gastric ulcer (1) Focal H.pylori gastritis (2)
|
Antral gastric ulcer (1) Focal H.pylori gastritis (5)
|
|
|
|
Duodenal
|
0
|
0
|
0
|
0
|
|
Endoscopic treatment or additional procedures
|
3
|
8
|
3
|
14
|
|
Esophageal
|
3
|
4
|
3
|
10
|
|
Barrett's (2)[*]
Varices (1)
|
Barrett's (2)[*]
Varices (2)
|
Barrett's (2)[*]
Varices (1)
|
|
|
Gastric
|
0
|
1
|
0
|
1
|
|
|
Fundic adenoma with HGD (1)
|
|
|
|
Duodenal
|
0
|
3
|
0
|
3
|
|
|
Angioectasia in D2 (1) Adenomatous polyp in D2 (2)
|
|
|
HGD, high-grade dysplasia
* Both medication and procedural changes
Additional lesions diagnosed with a forward-viewing gastroscope and missed with a
side-viewing duodenoscope included Barrett’s esophagus (2), esophageal candidiasis
(1), esophageal varices (1), reflux esophagitis (1), focal H. pylori-positive gastritis (2), and gastric ulcers in the antrum (2) and fundus (1). Additional
lesions missed with an oblique-viewing linear echoendoscope included Barrett’s esophagus
(2), esophageal candidiasis (1), esophageal varices (2), reflux esophagitis (1), esophageal
ulcer (1), focal H. pylori gastritis (5), gastric ulcer in the antrum (1), gastric adenoma with high-grade dysplasia
in the fundus (1), duodenal angioectasia (second part) (1), and adenomatous duodenal
polyps (second part) (2). Focal H. pylori gastritis was seen as focal erythema that histology from biopsies showed H. pylori. Finally, lesions missed by both non-forward-viewing endoscopes in a single procedure
included Barrett’s esophagus (2) and esophageal varices (1) ([Table 3]). Two lesions, a duodenal polyp and an ampullary adenoma, were visualized with a
side-viewing duodenoscope and not seen with the standard gastroscope. No upper gastrointestinal
malignancies were diagnosed. No adverse events were reported in any of the patients
undergoing standard EGD following a EUS or ERCP.
Discussion
ERCP and EUS are increasingly utilized in pancreaticobiliary exams. While these endoscopes
are required to traverse the upper gastrointestinal tract to obtain their images,
it is unclear if the endoscopist should be performing a detailed exam of the upper
gastrointestinal tract during the same procedure. Our study helps answer this question
as the literature to our knowledge is surprisingly sparse on this topic. In our study
we found that significant incidental upper gastrointestinal lesions is found when
a formal exam is performed with a gastroscope.
A recent study of 204 patients found that 22 % were found to have clinically meaningful
lesions on EGD prior to EUS for pancreaticobiliary indications and the authors of
the study supported performing an EGD for any patient undergoing EUS [3]. However, in the study, an EGD was performed before the EUS exam, and therefore
it is not known if the clinically meaningful lesions would have been detected by an
oblique-viewing echoendoscope without performing an EGD. In our study, an EGD was
performed after a linear EUS exam and resulted in additional lesions findings in 17/83
patients (20.5 %). Furthermore, no studies have evaluated the role of an EGD in detecting
clinically meaningful lesions when performed either before or after an ERCP. In our
study, an EGD with a gastroscope after an ERCP with a duodenoscope resulted in additional
lesions findings in 10/52 patients (19.2 %).
A previous study of 172 patients compared EGD and endoscopic ultrasound with radial
EUS for the evaluation of upper abdominal pain and demonstrated combined luminal findings
in 25 % of the patients [4]. Patients were randomized to undergo luminal examination with both a standard gastroscope
and an oblique-viewing radial echoendoscope by separate gastroenterologists in tandem
prior to sonographic examination. In the subset analysis, there were no overall differences
between the two scopes for detecting mucosal lesions, but the radial echoendoscope
missed several Barrett’s esophagus, gastric ulcers, and submucosal lesions. The ability
to take biopsies with the radial scope was also limited, requiring a 56 % conversion
rate to a standard endoscope. However, this study cohort only included patients who
were referred to gastroenterologists for diagnostic EGDs to evaluate their upper abdominal
pain, therefore, the findings cannot be extrapolated to asymptomatic patients and
patients referred for EUS for other indications.
Another study of 200 patients with dyspepsia demonstrated that oblique-viewing radial
EUS had sensitivity and specificity of 80 % and 95 %, respectively, for detecting
luminal lesions when compared to EGD [5]. In this study, patients who were referred for dyspepsia underwent radial EUS followed
by EGD to look for both luminal and extraluminal etiologies of their symptoms. Luminal
lesions that were missed by EUS included duodenal ulcers and reflux esophagitis. Given
that the primary goal of this study was to evaluate an EUS-based management strategy
for dyspepsia, only findings that accounted for dyspeptic symptoms were reported.
This study cohort included only patients with dyspepsia. Because clinically significant
lesions do not always cause symptoms, these findings do not translate to our study
population who were undergoing EUS for both symptomatic and asymptomatic indications.
Our study evaluated patients referred for ERCP and/or EUS. Although it is not known
how many patients had undergone previous upper endoscopic evaluation prior to the
procedures analyzed, our findings demonstrate the importance of performing an EGD
during ERCP and/or EUS. Our results among 168 patients showed that EGD with a forward-viewing
gastroscope yielded additional meaningful findings in 19 % (10 /52) of patients following
an ERCP with a duodenoscope, 20 % (17/83) of patients following a linear EUS, and
9 % (3/33) of patients utilizing both a duodenoscope and a linear echoendoscope. Our
findings coincide with previous published rates of incidental lesions requiring management
changes found during EGD performed for various reasons, which range from 22 % to 62 %,
but it is the first to show the high miss rate of significant lesions with both duodenoscopes
and linear EUS echoendoscopes [3]
[6]
[7].
Prior to data analysis, we hypothesized that nearly all of the missed lesions during
non-forward-viewing endoscopy would be esophageal given the semi-“blind” passage of
the scope through the narrowed tubular lumen of the esophagus compared to the stomach
and duodenum. However, 15/30 of the missed lesions (50 %) were found in the stomach
and duodenum, suggesting that luminal diameter was not the main factor contributing
to missed lesions.
Additional lesions diagnosed by EGD requiring endoscopic treatment included argon
plasma coagulation (APC) of an angioectasia, endoscopic mucosal resection of a gastric
adenoma with high-grade dysplasia, and variceal band ligation. Additional lesions
requiring further endoscopic surveillance included Barrett’s esophagus, esophageal
varices, and gastric ulcers. Additional significant medical interventions included
treatment for H. pylori, esophageal varices, and cirrhosis workup and management. One patient with a pancreatic
head cyst causing partial duodenal obstruction diagnosed on forward-viewing endoscopy
was admitted to the hospital for management of her symptoms.
In this study, we performed the EGD after the indicated ERCP or EUS procedure to maximize
time for the main procedure in the event that the procedure had to be terminated prematurely.
Previous data have suggested that performing standard upper endoscopy prior to EUS
may detect luminal lesions that will affect subsequent EUS in 9.8 % to 12 % of patients,
thus preventing potential complications during EUS [3]
[8]. However, other studies have shown EUS to be a safe procedure with a low complication
rate even if performed without a prior EGD [9]. In our study, zero adverse events/complications were experienced during non-forward-viewing
exams. It should be noted that these patients had no upper gastrointestinal symptoms.
Patients with upper gastrointestinal symptoms underwent EGD first and were not included
in this study.
This study strongly supports the notion that standard forward-viewing endoscopy should
be performed at the same session of pancreaticobiliary EUS and ERCP. This study did
not evaluate the increased cost of performing a standard EGD. The previously described
study on this topic did not evaluate cost effectiveness either [3]. The additional costs would be significant as there are costs associated with cleaning
the additional gastroscope, equipment to biopsy (e. g., biopsy forceps), provide additional
therapy (e. g., APC of lesions), physician fee for the additional procedure, etc.
However, the additional lesions discovered in this cohort were significant and would
likely be clinically significant in the future, adding to the cost of future gastrointestinal
healthcare (e. g., cost of gastrointestinal bleeding in incidentally found vascular
ectasias or varices, gastric cancer in the incidental gastric adenoma with high-grade
dysplasia, duodenal cancer in the incidental duodenal adenoma, etc). It is also possible
that some of the incidentally found lesions increased healthcare costs without clinical
benefit (e. g., enrolling patients with incidentally found non-dysplastic Barrett’s
esophagus that will not progress to neoplasia in a surveillance program, eradication
of H. pylori that never would have caused significant disease, etc.). Future studies are needed
to investigate the cost effectiveness of forward-viewing endoscopy at the time of
pancreaticobiliary EUS and ERCP.
This study also shows that in patients without upper gastrointestinal symptoms who
undergo pancreaticobiliary EUS or ERCP, the order of forward-viewing endoscopic exam
is irrelevant. There were no complications associated with the forward-viewing endoscopy
when performed after EUS or ERCP. There is a theoretical risk that an oblique or side-viewing
scope which traverses an unknown esophageal or duodenal stricture/lesion could possibly
lead to a perforation. For this theoretical risk only, we would recommend that the
forward-viewing endoscopy be performed before every pancreaticobiliary EUS and ERCP.
This study has certain limitations which should be noted, including the limitations
inherent in its retrospective design. However, all endoscopic findings for each exam
were recorded separately on the procedure report, thus the groups were not difficult
to compare. Another limitation is that this study only included one endoscopist’s
procedures. Other practicing therapeutic endoscopists at our institution were not
included in the study because their standard of care was to perform an EGD prior to
the EUS or ERCP. In addition, an inherent limitation for which we cannot account is
the theoretical subconscious decreased effort of the endoscopist to look for incidental
upper gastrointestinal tract lesions knowing that a forward-viewing endoscopy is going
to be performed. However, a significant number of lesions were discovered on EUS and
ERCP before forward-viewing endoscopy, which makes this less likely.
In summary, the current study demonstrates that non-forward-viewing duodenoscopes
and linear echoendoscopes miss a significant number of meaningful incidental upper
gastrointestinal luminal lesions. Performing an upper endoscopy with a forward-viewing
gastroscope at the time of ERCP or EUS leads to an increased yield of meaningful incidental
upper gastrointestinal lesions. Gastroenterologists who perform linear EUS or ERCP
should strongly consider performing a formal EGD with a gastroscope at the time of
the EUS or ERCP exam. Further prospective studies are warranted in order to make clinical
practice recommendations.